Exparel/bupivacaine mixture

Phase 3Small molecule

WWake Forest University Health Sciences

Exparel/bupivacaine mixture is one of 3 small molecule programs targeting OSA. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OSANot yet recruiting

OSAPhase 3

Not yet recruiting

Competition

Competitive Landscape

7 competitors in OSA

#DrugCompanyPhaseTrials

Lunesta

Akero Therapeutics

Phase 2

1 2

Exparel/bupivacaine mixture

WWake Forest University Health Sciences

Phase 3

1 3

Trazodone Hydrochloride

LLee's Pharmaceutical Limited

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Post-ApprovalNot yet recruiting

OSA

NCT07246642

Clinical

Trials by Indication[1]

OSA1 trial

IPP Placement & Intracavernosal Block

Not yet recruiting·WWake Forest University Health Sciences·Phase 4·NCT07246642·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Exparel/bupivacaine mixture. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Exparel/bupivacaine mixture compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Exparel/bupivacaine mixture. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Wake Forest University Health Sciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: WWake Forest University Health Sciences

Exparel/bupivacaine mixture

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

OSA1 trial

References

Drug Info

Quick Facts

Related News